Application of PDCA circular method in nursing quality management / 中国基层医药

Objective PDCA circular method was used to control the nursing quality in nursing level,service attitude,health education and hospital environment,so that nursing quality could be increasingly improved.Methods According to PDCA circular method,a repeated circular process,which includes plan,doing,check,action,helps us to find problems and improve our work at once.The patients' satisfaction to nursing was done by a questionnaire and P value was used to analyse the difference in statistics among three groups.Results The patients' satisfaction of our nursing had increased year by year.There was statistically significant difference(P

A prospective randomized trial comparing mitomycin C and vindesine and cisplatin versus pirarubicin and vindesine and cisplatin in the treatment of advanced non-small cell lung cancer / 中国肺癌杂志

<p><b>BACKGROUND</b>To evaluate the response, adverse effects and survival of MVP regimen and TVP regimen.</p><p><b>METHODS</b>Sixty six patients with advanced non-small cell lung cancer were randomized into two groups:MVP arm (32 patients, mitomycin C 6-8 mg/m² d1, vindesine 2-3 mg/m² d1 and d8, cisplatin 70-80 mg/m² d1) and TVP arm (34 patients, pirarubicin 40-50 mg/m² d1, vindesine and cisplatin were the same as arm MVP). Characteristics of the patients were similar in two arms. All patients received two to four cycles of chemotherapy.</p><p><b>RESULTS</b>The overall responses were 34% (11/32) in the MVP arm and 56% (19/34) in the TVP arm. There were 1 complete response, 10 partial responses in the MVP arm and 1 complete response, 18 partial responses in the TVP arm. TVP regimen appeared to have a higher objective response, but no statistically significant difference in the response was observed between two regimens (Chi-square=2.269, P=0.132). Main side effects were hematological toxicities. Grade III+IV hematological toxicities were significantly higher in the patients of arm TVP than arm MVP, especially neutropenia (79% vs 44%, Chi-square=7.458, P=0.006). Median survival time was 12 months vs 8 months, and 1-, 2-, 3-year survival rates were 53% vs 24% (Chi-square=4.943, P=0.026), 17% vs 6%, 6% vs 0, for arm TVP and arm MVP, respectively..</p><p><b>CONCLUSIONS</b>MVP regimen has a lower response rate and longer survival time but less hematological toxicities than TVP regimen. The results suggest MVP regimen is a safe and active regimen for advanced non-small cell lung cancer.</p>